December 14, 2018, Law360

Brianne Bharkhda and Natalie Derzko are quoted in Law360 regarding two Federal Circuit decisions that have cleared up lingering questions about patents can be invalidated under the double-patenting doctrine and identified situations where it does not apply. Ms. Bharkhda says, "I would characterize the two decisions as further defining the contours of the ...

December 10, 2018, Covington Alert

On December 7, 2018, the Federal Circuit issued two highly-anticipated decisions clarifying the application of the obviousness-type double patenting doctrine: Novartis AG v. Ezra Ventures LLC (patent term extension ("PTE")), and Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc. (pre-Uruguay Round Agreements Act ("URAA") versus post-URAA ...

June 20, 2018

NEW YORK—Covington advised Boston Children's Hospital in its monetization of a portion of its royalties relating to Vonvendi, a recombinant drug used to treat a common bleeding disorder called von Willebrand disease. The purchaser, Barings Alternative Investments, part of Barings LLC, on behalf of institutional investors, paid $51.5 million. Boston Children’s ...

April 20, 2015

NEW YORK — Covington advised the underwriters in the $76.8 million initial public offering of common stock of Cidara Therapeutics, Inc. Shares of Cidara trade on the NASDAQ Global Market under the ticker “CDTX.” Cidara is a biopharmaceutical company focused on the discovery, development and commercialization of anti-infectives for treatment of diseases ...

June 13, 2013, Inside Medical Devices

Kurt Calia and Allison Kerndt also contributed to this post. The Supreme Court released its decision in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. (Appeal No. 12-398) earlier today.  The question presented was whether human genes are patent eligible.  In a unanimous decision, the Supreme Court held that naturally occurring...… ...

June 13, 2013, InsideMedicalDevices Blog

Panel Moderator, April 2013, ABA-IPL 28th Annual Intellectual Property Law Conference, Arlington, VA

January 18, 2013, Covington E-Alert

March 23, 2012, Covington E-Alert

November 10, 2011

WASHINGTON, DC, November 10, 2011 — Covington & Burling represented Salix Pharmaceuticals, Ltd. in its agreement to acquire Oceana Therapeutics, Inc., a privately held global provider of gastroenterology and urology therapeutics, for $300 million in cash. “The acquisition of Oceana expands our product portfolio of innovative products, furthers the ...

June 2011, Emerging Leaders Workshop: Hitting the Mark in New Product Commercialization session at the BIO 2011 Convention, Washington, DC

June 25, 2010

NEW YORK, June 25, 2010 — Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc. today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress. Covington & ...

April 30, 2010

<?xml:namespace prefix="o"?><o:p>WASHINGTON, DC, April 30, 2010 — Covington & Burling LLP is pleased to announce the promotion of three lawyers to of counsel.</o:p> <o:p>The new of counsels are as follows:</o:p> <o:p>Natalie Derzko (Washington) practices in the areas of intellectual property, strategic counseling, due diligence, patent prosecution, patent ...

9/24/2009

NEW YORK, September 24, 2009 — Boehringer Ingelheim, and its US animal health business Boehringer Ingelheim Vetmedica, Inc., has entered into an agreement with Pfizer to acquire certain assets of Wyeth’s Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger. Covington & Burling LLP represented Boehringer Ingelheim on the ...

April 2009, Hopkins Biotech Network 2009 Discussion Series, Johns Hopkins University, Rockville, MD

October 2008, Patent Resources Group, Albuquerque, New Mexico

June 2008, International Food Technology (IFT) Annual Meeting, New Orleans, LA

March 2008, Commentator at 16th Annual Conference on Intellectual Property Law & Policy, Fordham Law School, New York, NY

January 2008, Pharma/Biotech IP Due Diligence Conference, New York, NY

September 2007, FDA Boot Camp, Chicago, IL

July 2007, FDA Boot Camp, Boston, MA

April 9, 2007, Covington E-Alert

March 2007, FDA Boot Camp, New York, NY

February 1, 2007

NEW YORK, NY, February 1, 2007 — Covington & Burling LLP advised Pfizer in the acquisition of BioRexis, a privately held biopharmaceutical company. The transaction is expected to close in the first or second quarter of 2007. The financial terms of the transaction were not disclosed.BioRexis is developing long-acting GLP-1 receptor agonists for the potential ...

9/13/2006

WASHINGTON, D.C., September 13, 2006 —  Covington represented both Eisai Co., Ltd. and Eisai Inc. in the recent $205 million product acquisition agreement with Ligand Pharmaceuticals.  Eisai obtained exclusive global rights to four products, including ONTAK®, Targretin® capsules, Targretin® 1% gel and Panretin® 0.1% gel.  This acquisition will help to ...

June 2005, Smithsonian Institution, Washington, DC

March 2005, Paperboard Packaging Council Meeting, Washington, DC

February 2005, Environmental Technology Symposium, Temple University, Philadelphia, PA

2005, 45 IDEA 165

October 2004, Maximizing Pharmaceutical Patent Life Cycles, New York

2004, 20 Santa Clara Computer and High Tech Law Journal 347

2003, 44 IDEA 1

July 2003, 21(7) Nature Biotechnology 823

Fall 2003-2005, Biotech Boot Camp, ASM Resources Inc. in Bethesda, MD

February 1998, 76 Managing Intell. Prop. 32

1996, 33 Alberta L. Rev. 58 (translated by Julie Dagenais Blackburn as Le Programme de Clercs à la Cour suprême du Canada, 36 Cahier de Droit 765)

1996, 20 Harv. Envtl. L. Rev. 3

1994, 39 McGill L.J. 144

1993, 8 Intell. Prop. J. 31